In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reed Miller

Deputy Editor

Washington, DC
Reed, deputy editor for commercial and R&D, got his first real job in journalism in 2000 with The Gray Sheet, then part of FDC Reports, based outside of Washington, DC, and has been covering medical technology ever since. His primary focus has been clinical trials and new product development, so he has covered innumerable FDA advisory panel meetings and Medicare coverage decisions. Mixed in to his many years with The Gray Sheet, Reed spent a year in Massachusetts with HCPro in that company’s pharma compliance editorial group, and three years as a reporter for theheart.org, when it was the best news source for cardiologists. In 2015, he’s became deputy editor of Clinica, continuing to track the bewildering and rapidly evolving universe of new medical technology, from IVDs to artificial hearts, from pre-clinical trials to commercialization. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.
Advertisement
Set Alert for Articles By Reed Miller

Latest From Reed Miller

New Data Confirm Safety Of GT Medical’s GammaTile Therapy For Brain Tumors

GT Medical is touting results from a validation study showing its GammaTile therapy controls the regrowth of brain tumors with a low rate of adverse events.

Clinical Trials Research & Development

Manufacturers Support CMS’ New TAVR National Coverage Decision

CMS has completed its new national Medicare Coverage with Evidence Development policy for transcatheter aortic valve replacement. The final decision memo largely maintains the recommendations from the draft version released in March, including more flexible criteria for centers establishing TAVR programs, while emphasizing the importance of the interdisciplinary heart team for decision-making about valve replacement.

Medicare Reimbursement

Global Device Approvals Snapshot: 18-24 June 2019

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. The week of 18-24 June was very slow for approvals, with no new PMAs, panel-track PMA supplements, or de novos.

Approvals Innovation

Device Week, 20 June 2019: ADA 2019 Key Players; Trial Results From Global Kinetics And Myriad Genetics

In this edition of Device Week, Medtech Insight's Catherine Longworth chats with Marion Webb about her upcoming Market Intelligence story based on interviews with the biggest players in the diabetes market at the recent annual American Diabetes Association meeting. And Reed Miller discusses Global Kinetics' recent data on its Personal KinetiGraph that can help identify Parkinson's patients most likely to benefit from device-assisted therapy and Myriad Genetics' POLO trial results.

Device Week Diabetic Care

Global Kinetics’ Personal KinetiGraph Identifies Parkinson’s Patients Suitable For Deep Brain Stimulation

A new study shows the Personal KinetiGraph wearable monitor can help clinicians identify the Parkinson’s disease patients most likely to benefit from device-assisted therapies, including deep brain stimulation.

Neurology Clinical Trials

Global Device Approvals Snapshot: 11-17 June 2019

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker, including a PMA supplement for Agilent’s PD-L1 IHC 22C3 pharmDx companion diagnostic for Merck’s Keytruda (pembrolizumab), an anti-PD-1 drug, for patients with head and neck squamous cell carcinoma. The US FDA also approved a supplement for the Cochlear Nucleus Profile Plus Series Cochlear Implant, designed to be safe with magnetic resonance imaging.

Approvals Innovation
See All
Advertisement
UsernamePublicRestriction

Register